ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Bioorganic & Medicinal Chemistry
Volume 12, Issue 21, 1 November 2004, Pages 5711-5717
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (309 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmc.2004.07.068    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2004 Elsevier Ltd All rights reserved.

Synthesis and anticonvulsant evaluation of some new 2-substituted-3-arylpyrido[2,3-d]pyrimidinones

David C. Whitea, Thomas D. Greenwooda, Aaron L. Downeya, Jeffrey R. Bloomquistc and James F. Wolfea, b, Corresponding Author Contact Information, E-mail The Corresponding Author

aDepartment of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212, USA bDivision of Biomedical Sciences, Edward Via Virginia College of Osteopathic Medicine, 2265 Kraft Drive, Blacksburg, VA 24060, USA cDepartments of Entomology and Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0319, USA

Received 23 October 2003; 
accepted 15 July 2004. 
Available online 21 September 2004.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Graphical abstract

Thumbnail image

Abstract

A series of 2-substituted-3-arylpyrido[2,3-d]pyrimidinones was prepared for evaluation as potential anticonvulsants. In murine screening, compounds 4ac having a 2-oxo-2-(4-pyridyl)ethyl group in the 2-position and a 2-substituted phenyl moiety at the 3-position of the pyridopyrimidinone system displayed the most potent anti-seizure activity in both the maximal electroshock (MES) and pentylenetetrazol (scPTZ) tests at doses in the 3–10 mg/kg range. Compound 4c showed no agonist activity at the GABAA receptor and was unable to block presynaptic sodium and calcium channels in vitro.

Article Outline

1. Introduction
2. Results and discussion
2.1. Synthesis
2.2. Pharmacological evaluation
3. Conclusions
4. Experimental
4.1. General
4.2. General procedure for the preparation of 2-methyl-3-arylpyrido[2,3-d]-4(3H)-pyrimidinones
4.3. 2-Methyl-3-phenylpyrido[2,3-d]-4(3H)-pyrimidinone (3d)
4.4. 2-Methyl-3-(2-methylphenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (3a)
4.5. 2-Methyl-3-(2-chlorophenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (3b)
4.6. General procedure for the acylation of 2-methyl-3-arylpyrido[2,3-d]-4(3H)-pyrimidinones
4.7. 2-[2-Oxo-2-(4-pyridyl)ethyl]-3-(2-chlorophenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (4b)
4.8. 2-[2-Oxo-2-(4-pyridyl)ethyl]-3-(2-bromophenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (4c)
4.9. 2-[2-Oxo-2-(4-pyridyl)ethyl]-3-phenylpyrido[2,3-d]-4(3H)-pyrimidinone (4d)
4.10. 2-(2-Oxo-2-phenylethyl)-3-(2-methylphenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (4e)
4.11. 2-[2-(4-Pyridyl)ethenyl]-3-(2-methylphenyl)pyrido[2,3-d]-4(3H)-pyrimidinone (5b)
4.12. Pharmacology
4.13. In vitro biological assays
Acknowledgements
References




Bioorganic & Medicinal Chemistry
Volume 12, Issue 21, 1 November 2004, Pages 5711-5717
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.